According to HUTCHMED's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.0667. At the end of 2022 the company had a P/E ratio of -6.87.
Year | P/E ratio | Change |
---|---|---|
2022 | -6.87 | -75.64% |
2021 | -28.2 | -19.33% |
2020 | -35.0 | 7.87% |
2019 | -32.4 | -19.62% |
2018 | -40.4 | -77.99% |
2017 | -183 | -235.11% |
2016 | 136 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.